Agosti E, Antonietti S, Zeppieri M, Ius T, Fiorindi A, Tel A
J Clin Med. 2024; 13(9).
PMID: 38731241
PMC: 11084907.
DOI: 10.3390/jcm13092711.
Kesari S, Wang F, Juarez T, Ashili S, Patro C, Carrillo J
Sci Rep. 2023; 13(1):7317.
PMID: 37147496
PMC: 10163028.
DOI: 10.1038/s41598-023-34404-4.
Young K, Nielsen T, Bulosan H, Thorne T, Ogasawara C, Birkeland A
Laryngoscope Investig Otolaryngol. 2022; 7(5):1280-1291.
PMID: 36258855
PMC: 9575061.
DOI: 10.1002/lio2.906.
Zhao T, Siu I, Williamson T, Zhang H, Ji C, Burger P
J Pathol. 2021; 255(1):72-83.
PMID: 34124783
PMC: 9534552.
DOI: 10.1002/path.5739.
Verma S, Vadlamani S, Shamim S, Barwad A, Rastogi S, Arun Raj S
Clin Sarcoma Res. 2020; 10(1):28.
PMID: 33308288
PMC: 7733273.
DOI: 10.1186/s13569-020-00149-1.
Chordoma: A Case Report and Review of Literature.
Noor A, Bindal P, Ramirez M, Vredenburgh J
Am J Case Rep. 2020; 21:e918927.
PMID: 31969553
PMC: 6998794.
DOI: 10.12659/AJCR.918927.
Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
Morimoto Y, Tamura R, Ohara K, Kosugi K, Oishi Y, Kuranari Y
J Neurooncol. 2019; 144(1):65-77.
PMID: 31240525
DOI: 10.1007/s11060-019-03221-z.
Active receptor tyrosine kinases, but not Brachyury, are sufficient to trigger chordoma in zebrafish.
DAgati G, Cabello E, Frontzek K, Rushing E, Klemm R, Robinson M
Dis Model Mech. 2019; 12(7).
PMID: 31221659
PMC: 6679381.
DOI: 10.1242/dmm.039545.
Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review.
Meng T, Jin J, Jiang C, Huang R, Yin H, Song D
Front Oncol. 2019; 9:30.
PMID: 30775316
PMC: 6367227.
DOI: 10.3389/fonc.2019.00030.
The Importance of the Hedgehog Signaling Pathway in Tumorigenesis of Spinal and Cranial Chordoma.
Akhavan-Sigari R, Schulz-Schaeffer W, Angelika Harcej A, Rohde V
J Clin Med. 2019; 8(2).
PMID: 30769952
PMC: 6406847.
DOI: 10.3390/jcm8020248.
Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma.
Ribeiro M, de Sousa M, Hanna S, Maldaun M, Kurimori C, Lima L
Case Rep Oncol Med. 2018; 2018:4290131.
PMID: 29850323
PMC: 5914121.
DOI: 10.1155/2018/4290131.
Chordoma: The Quest for Better Treatment Options.
Heery C
Oncol Ther. 2017; 4(1):35-51.
PMID: 28261639
PMC: 5315072.
DOI: 10.1007/s40487-016-0016-0.
Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series.
Lipplaa A, Dijkstra S, Gelderblom H
Clin Sarcoma Res. 2016; 6:19.
PMID: 27822356
PMC: 5088663.
DOI: 10.1186/s13569-016-0059-x.
Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.
Colia V, Provenzano S, Hindi N, Casali P, Stacchiotti S
Rep Pract Oncol Radiother. 2016; 21(4):361-9.
PMID: 27330421
PMC: 4899415.
DOI: 10.1016/j.rpor.2015.12.005.
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry D, Zuercher W
J Pathol. 2016; 239(3):320-34.
PMID: 27102572
PMC: 4922416.
DOI: 10.1002/path.4729.
Mutation Analysis of Nine Chordoma Specimens by Targeted Next-Generation Cancer Panel Sequencing.
Fischer C, Scheipl S, Zopf A, Niklas N, Deutsch A, Jorgensen M
J Cancer. 2015; 6(10):984-9.
PMID: 26366211
PMC: 4565847.
DOI: 10.7150/jca.11371.
Novel targeted therapies in chordoma: an update.
Di Maio S, Yip S, Al Zhrani G, Alotaibi F, Al Turki A, Kong E
Ther Clin Risk Manag. 2015; 11:873-83.
PMID: 26097380
PMC: 4451853.
DOI: 10.2147/TCRM.S50526.
Sustained response of a clivus chordoma to erlotinib after imatinib failure.
Houessinon A, Boone M, Constans J, Toussaint P, Chauffert B
Case Rep Oncol. 2015; 8(1):25-9.
PMID: 25762924
PMC: 4342859.
DOI: 10.1159/000371843.
[Novel molecular aspects of chordomas].
Scheil-Bertram S
Pathologe. 2014; 35 Suppl 2:237-41.
PMID: 25394972
DOI: 10.1007/s00292-014-1986-z.
